<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26436081</article-id><article-id pub-id-type="pmc">4581135</article-id><article-id pub-id-type="publisher-id">ABR-4-167</article-id><article-id pub-id-type="doi">10.4103/2277-9175.162544</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Naini</surname><given-names>Afsoon Emami</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Asiabi</surname><given-names>Reza Ebrahimi Kord</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Keivandarian</surname><given-names>Noushin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Moeinzadeh</surname><given-names>Firouzeh</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1">Department of Internal Medicine, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Firouzeh Moeinzadeh, Department of Internal Medicine, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="moinzade@resident.mui.ac.ir">moinzade@resident.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>10</day><month>8</month><year>2015</year></pub-date><volume>4</volume><elocation-id>167</elocation-id><history><date date-type="received"><day>09</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Naini.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>End stage renal disease (ESRD) is a state of micro inflammation that attenuates patient's life span and quality of life. Inflammatory markers like interlukin 6 (IL-6) and C- reactive protein (CRP) can predict inflammatory state in ESRD patients. Dietary limitations are risk factors for omega-3 deficiency in these patients. Omega-3 supplementation is an attractive material that proposed in inflammation modulation. The aim of this study is evaluation of effect of omega-3 supplementation on IL-6 and CRP level in chronic ambulatory peritoneal dialysis (CAPD) patients.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>This randomized controlled double-blind clinical trial is performed in 40 CAPD patients in two academic hospitals in Isfahan, Iran. One group received 1000 mg omega-3 capsule (each capsule contains 180 mg Eicosapentanoic and 120 mg Dosahexanoic acid) three times a day orally for 8 weeks (<italic>n</italic> = 20) and the other matched group by placebo (<italic>n</italic> = 20). Serum level of IL-6 and quantitative CRP (Q-CRP) were measured in beginning and the end of the study. Finally all data were analyzed by SPSS version 18.</p></sec><sec id="st3"><title>Results:</title><p>Mean age of patients was 53 years old in omega-3 group patients and 54 years old in placebo group. There were not any differences in CRP and IL-6 level in the beginning and the end of study between two groups (<italic>P</italic>: 0.81 and 0.10 for CRP and 0.26 and 0.23 for IL-6, respectively).</p></sec><sec id="st4"><title>Conclusion:</title><p>Omega-3 supplementation did not effect on inflammatory markers (Q-CRP and IL-6) in CAPD patients after 8 weeks.</p></sec></abstract><kwd-group><kwd>C&#x02013; reactive protein</kwd><kwd>chronic ambulatory peritoneal dialysis</kwd><kwd>interlukin 6</kwd><kwd>omega&#x02013;3</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Mortality in end stage renal disease patients (ESRD) is correlated with traditional and nontraditional or &#x0201c;novel&#x0201d; risk factors.[<xref rid="ref1" ref-type="bibr">1</xref>] In Framingham Heart study, some characteristics like sex, hypertension, age, diabetes mellitus, smoking regarded as traditional risk factors. In addition, in some researches, some other risk factors including hypoalbuminemia, increased fibrinogen level and inflammation had related to cardiovascular mortality and morbidity referred as non-traditional risk factors.[<xref rid="ref2" ref-type="bibr">2</xref>] Susceptibility to increasing inflammatory process look multiple reasons, perhaps of dialysis or non-dialysis factors.[<xref rid="ref3" ref-type="bibr">3</xref>] In uremic patients, cytotoxines can generate excess oxidative stress that ultimately produce reactive oxygen species (ROS).[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] Therefore, advanced glycation endproducts (AGEs) are produced and convert short-lasting inflammatory responses to sustained pro-inflammatory reactions that induce atherosclerosis and calcifications.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Some inflammatory biomarkers are recognized in these processes that C-reactive protein (CRP) is the attractive molecules between them.[<xref rid="ref8" ref-type="bibr">8</xref>] ESRD patients have elevated level of CRP due to dialysis membranes, fluid overload or chronic persistent infections caused by grafts and catheters.[<xref rid="ref9" ref-type="bibr">9</xref>] According to one study, serum CRP level is associated with higher mortality independent of serum albumin level.[<xref rid="ref10" ref-type="bibr">10</xref>] Another biomarker that was proposed as an useful molecule is interlukin-6 (IL-6) that acts as pro- and anti-inflammatory cytokine.[<xref rid="ref11" ref-type="bibr">11</xref>] Serum level of IL6 in ESRD patients increases and its level do not change pre and post hemodialysis.[<xref rid="ref12" ref-type="bibr">12</xref>] Some materials including fish oil could reduce atherosclerosis and inflammation <italic>via</italic> inhibition of lipid peroxidation.[<xref rid="ref13" ref-type="bibr">13</xref>] However, some investigations describe the benefits of omega-3 supplementation in prevention of inflammation progression in hemodialysis patients.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref>] But few studies are designed for effect of omega-3 in peritoneal dialysis patients, as a modality for renal replacement therapy.[<xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] In this study, we decided to evaluate the effect of omega-3 on IL6 and CRP, as inflammatory parameters, on CAPD patients.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>This randomized controlled double-blind clinical trial was carried out in two CAPD centers in two university hospitals in Isfahan, Iran. Patients with ESRD on continuous ambulatory peritoneal dialysis for at least 3 months and at least 18 years old enrolled in the study after agreement of consent form. If the patients had thrombocytopenia (PLT &#x0003c; 100,000/mm<sup>3</sup>), steatorrhea, malignancy, abnormal coagulation profile or need for anticoagulation therapy, they exclude from the study.</p><p>All patients those were enrolled into the study were divided into two groups as shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. In case group (<italic>N</italic> = 40), they receive omega-3 capsule, three times a day for 2 months. Each 1 gram capsule (Omega-3, Zahravi co. Tabriz. Iran) contains Eicosapentanoic (180 mg) and Dosahexanoic (120 mg). In placebo group (<italic>N</italic> = 40) they receive placebo capsule, manufactured by the same as case group. All capsules have opaque enveloped and each patient receives the drugs for 2 months. After this, patient is admitted for evaluation of compliance, side effects and managing some possible problems. The next drugs enveloped were given them 1 month later. Serum levels of Interlukin-6 (IL-6) and C-reactive protein (CRP) were measured at beginning and the end of the study using auto analyzer, by standard kits.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow diagram of the study process and patient selection</p></caption><graphic xlink:href="ABR-4-167-g001"/></fig><p>Patients were notified of the possibility of adverse effects such as abdominal pain, bloating, diarrhea, nausea and bleeding during the study. Incidence of these symptoms was evaluated by a specific questionnaire.</p><sec id="sec2-1"><title>Statistical analysis</title><p>This study has approved by Isfahan Kidney Diseases Research Center (project no. 391350) and ethical committee of Isfahan University of Medical Sciences. This study was registered in Iranian registry of clinical trials with ID number: IRCT201303052417N11.</p><p>All statistical analyses were performed with SPSS software (version 18.0 SPSS Inc, Chicago, IL, USA). Statistical analysis was done with &#x003c7;<sub>2</sub> test, paired <italic>t</italic>-test and analysis of variance (ANOVA). A 2-sided probability value of &#x0003c; 0.05 was considered statistically significant and a 95% confidence interval was used.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>A total of 40 patients allowed to participating in this study. All candidates were randomized into either Omega-3 therapy (<italic>n</italic> = 20) or placebo therapy (<italic>n</italic> = 20). During this study, any patient describes significant side effects leading to drug discontinuation in both groups.</p><p>Demographic and baseline characteristics of all patients included in the study are shown in <xref ref-type="table" rid="T1">Table 1</xref>. Our data showed no significant difference between two groups regarding age, sex, body mass index (BMI), medication usage and cause of renal failure.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics of CAPD Patients at the start of study</p></caption><graphic xlink:href="ABR-4-167-g002"/></table-wrap><p>After 2 months, mean serum level of CRP were not shown significant differences analytic (<italic>P</italic> = 0.047 and 0.054 respectively). This finding was similar about IL-6 after 2 months supplementation between omega-3 and placebo groups (<italic>P</italic> = 0.064 and 0.066). Details of data are demonstrated in Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of Interlukin-6 (IL-6) and quantitative C-reactive protein (Q-CRP) in baseline and at 8 weeks in two groups</p></caption><graphic xlink:href="ABR-4-167-g003"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparison of Delta Interlukin-6 (IL-6) and Delta quantitative C-reactive protein (Q-CRP) in baseline and at 8 weeks in two groups</p></caption><graphic xlink:href="ABR-4-167-g004"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Inflammation in ESRD patients is a destructive state that has an important role in atherosclerosis and cardiovascular diseases. This process is mediated by some mediators like Interleukins, CRP and tumor necrotizing factor.[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref>] Some studies suggest that CRP is not only a marker of inflammation.</p><p>Inflammation but also be a direct mediator of vascular disease.[<xref rid="ref20" ref-type="bibr">20</xref>] On the other hand, inflammation is a common process in renal failure that could predict outcome in chronic kidney diseases, in all stages.[<xref rid="ref21" ref-type="bibr">21</xref>] Therefore, we can suppress this process with using substances that can suppress inflammation. Between these, omega-3,[<xref rid="ref18" ref-type="bibr">18</xref>] magnesium,[<xref rid="ref22" ref-type="bibr">22</xref>] Zinc[<xref rid="ref23" ref-type="bibr">23</xref>] and dietary antioxidants[<xref rid="ref24" ref-type="bibr">24</xref>] have been studied till now. Omega-3 fatty acids act via modulation of cell membrane and synthesis of lipid mediators. Omega-3 fatty acid is derived from &#x003b1;-linolenic acid (ALA) then converts to eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) in endoplasmic reticulum and peroxisomes, respectively.[<xref rid="ref25" ref-type="bibr">25</xref>] Ultimately, anti inflammatory effects of omega-3 derived from down regulation of proinflammatory cytokines and cell surface molecules areinvolved in cell adhesion and activation.[<xref rid="ref26" ref-type="bibr">26</xref>] For this reason, fish oil is used for some inflammatory states like in rhomatoid arthritis,[<xref rid="ref27" ref-type="bibr">27</xref>] crohn,[<xref rid="ref28" ref-type="bibr">28</xref>] Ig A nephropathy,[<xref rid="ref29" ref-type="bibr">29</xref>] sepsis,[<xref rid="ref30" ref-type="bibr">30</xref>] too.</p><p>Some studies are performed in end stage renal disease patients in order to evaluation and benefit assessment of omega-3 on inflammatory processes. Madsen <italic>et al.</italic>,[<xref rid="ref31" ref-type="bibr">31</xref>] demonstrate that there was no significant differences in serum level of CRP in ESRD patients on hemodialysis after daily supplementation with 2.4 g omega-3 for 8 weeks compared to placebo group. Tayyebi <italic>et al.</italic>,[<xref rid="ref32" ref-type="bibr">32</xref>] describe similar findings in their study but reveal significant decreases in serum level of TNF-&#x003b1; after 3 g omega-3 per day. Although Sahinarslan described that serum level of IL-6, TNF-&#x003b1; and CRP had no differences in two types of dialysis (hemodialysis or peritoneal dialysis), the most studies did in hemodialysis patients.[<xref rid="ref32" ref-type="bibr">32</xref>] In our study, we did not find any significant changes in serum level of IL-6 and CRP after supplementation with omega-3. This finding is against the Tayyebi study, although that study was done in hemodialysis patients.[<xref rid="ref33" ref-type="bibr">33</xref>]</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>Omega-3 supplementation did not have effect on inflammatory markers (Q-CRP and IL-6) in CAPD patients after 8 weeks.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Isfahan University of Medical Sciences</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Pecoits-Filho</surname><given-names>R</given-names></name><name><surname>Lindholm</surname><given-names>B</given-names></name><name><surname>Stenvinkel</surname><given-names>P</given-names></name></person-group><article-title>Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease</article-title><source>Scand J Urol Nephrol</source><year>2004</year><volume>38</volume><fpage>405</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15764253</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Fried</surname><given-names>LF</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Manolio</surname><given-names>TA</given-names></name><name><surname>Peterson</surname><given-names>D</given-names></name><name><surname>Stehman-Breen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>1737</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15827312</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenvinkel</surname><given-names>P</given-names></name><name><surname>Ketteler</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Lindholm</surname><given-names>B</given-names></name><name><surname>Pecoits-Filho</surname><given-names>R</given-names></name><name><surname>Riella</surname><given-names>M</given-names></name><etal/></person-group><article-title>IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia--the good, the bad, and the ugly</article-title><source>Kidney Int</source><year>2005</year><volume>67</volume><fpage>1216</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15780075</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betjes</surname><given-names>MG</given-names></name></person-group><article-title>Immune cell dysfunction and inflammation in end-stage renal disease</article-title><source>Nat Rev Nephrol</source><year>2013</year><volume>9</volume><fpage>255</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">23507826</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Canaud</surname><given-names>B</given-names></name><name><surname>Eckardt</surname><given-names>KU</given-names></name><name><surname>Stenvinkel</surname><given-names>P</given-names></name><name><surname>Wanner</surname><given-names>C</given-names></name><name><surname>Zoccali</surname><given-names>C</given-names></name></person-group><article-title>Oxidative stress in end-stage renal disease: An emerging threat to patient outcome</article-title><source>Nephrol Dial Transplant</source><year>2003</year><volume>18</volume><fpage>1272</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12808161</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axelsson</surname><given-names>J</given-names></name><name><surname>Qureshi</surname><given-names>AR</given-names></name><name><surname>Suliman</surname><given-names>ME</given-names></name><name><surname>Honda</surname><given-names>H</given-names></name><name><surname>Pecoits-Filho</surname><given-names>R</given-names></name><name><surname>Heimbu&#x000a8;rger</surname><given-names>O</given-names></name><etal/></person-group><article-title>Truncal fat mass as a contributor to inflammation in end-stage renal disease</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>80</volume><fpage>1222</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15531669</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavafi</surname><given-names>M</given-names></name></person-group><article-title>Diabetic nephropathy and antioxidants</article-title><source>J Nephropathol</source><year>2013</year><volume>2</volume><fpage>20</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24475422</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwedler</surname><given-names>S</given-names></name><name><surname>Filep</surname><given-names>J</given-names></name><name><surname>Galle</surname><given-names>J</given-names></name><name><surname>Wanner</surname><given-names>C</given-names></name><name><surname>Potempa</surname><given-names>LA</given-names></name></person-group><article-title>C-Reactive Protein: A family of proteins to regulate cardiovascular function</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>47</volume><fpage>212</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16431250</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pupim</surname><given-names>LB</given-names></name><name><surname>Himmelfarb</surname><given-names>J</given-names></name><name><surname>McMonagle</surname><given-names>E</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><name><surname>Ikizler</surname><given-names>TA</given-names></name></person-group><article-title>Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><fpage>2371</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15149350</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasri</surname><given-names>H</given-names></name></person-group><article-title>Serum C reactive protein (CRP) in association with various nutritional parameters in maintenance hemodialysis patients</article-title><source>Bratisl Lek Listy</source><year>2005</year><volume>106</volume><fpage>390</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16642663</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Horiuchi</surname><given-names>S</given-names></name><name><surname>Topley</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Fuller</surname><given-names>G</given-names></name></person-group><article-title>The soluble interleukin 6 receptor: Mechanisms of production and implications in disease</article-title><source>FASEB J</source><year>2001</year><volume>15</volume><fpage>43</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">11149892</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memoli</surname><given-names>B</given-names></name><name><surname>Romano</surname><given-names>G</given-names></name><name><surname>D'Arcangelo</surname><given-names>R</given-names></name><name><surname>Del Prete</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>P</given-names></name><name><surname>Procino</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Role of Interleukin-6 and of Its Soluble Receptors in the Biocompatibility of Dialysis Treatment</article-title><source>Semin Nephrol</source><year>2004</year><volume>24</volume><fpage>492</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15490418</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><article-title>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S)</article-title><source>Lancet</source><year>1994</year><volume>344</volume><fpage>1383</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7968073</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tayyebi-Khosroshahi</surname><given-names>H</given-names></name><name><surname>Houshyar</surname><given-names>J</given-names></name><name><surname>Tabrizi</surname><given-names>A</given-names></name><name><surname>Vatankhah</surname><given-names>AM</given-names></name><name><surname>Razzagi Zonouz</surname><given-names>N</given-names></name><name><surname>Dehghan-Hesari</surname><given-names>R</given-names></name></person-group><article-title>Effect of Omega-3 Fatty Acid on Oxidative Stress in Patients on Hemodialysis</article-title><source>Iran J Kidney Dis</source><year>2010</year><volume>4</volume><fpage>322</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20852375</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekovic</surname><given-names>PG</given-names></name><name><surname>Milutinovic</surname><given-names>RZ</given-names></name><name><surname>Gluvic</surname><given-names>Z</given-names></name><name><surname>Lackovic</surname><given-names>M</given-names></name><name><surname>Medic</surname><given-names>DR</given-names></name><name><surname>Glibetic</surname><given-names>M</given-names></name></person-group><article-title>Inflammation, nutritional status PUFA profile and outcome in hemodialysis patients</article-title><source>Arch Biol Sci</source><year>2012</year><volume>64</volume><fpage>1173</fpage><lpage>80</lpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filiopoulos</surname><given-names>V</given-names></name><name><surname>Hadjiyannakos</surname><given-names>D</given-names></name><name><surname>Takouli</surname><given-names>L</given-names></name><name><surname>Metaxaki</surname><given-names>P</given-names></name><name><surname>Sideris</surname><given-names>P</given-names></name><name><surname>Vlassopoulos</surname><given-names>D</given-names></name></person-group><article-title>Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis</article-title><source>Int J Artif Organs</source><year>2009</year><volume>32</volume><fpage>872</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">20037892</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taheri</surname><given-names>S</given-names></name><name><surname>Keyvandarian</surname><given-names>N</given-names></name><name><surname>Moeinzadeh</surname><given-names>F</given-names></name><name><surname>Mortazavi</surname><given-names>M</given-names></name><name><surname>Emami Naini</surname><given-names>AE</given-names></name></person-group><article-title>The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients</article-title><source>Adv Biomed Res</source><year>2014</year><fpage>3</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">24600594</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>A</given-names></name><name><surname>Moe</surname><given-names>S</given-names></name></person-group><article-title>Review of the Effects of Omega-3 Supplementation in Dialysis Patients</article-title><source>Clin J Am Soc Nephrol</source><year>2006</year><volume>1</volume><fpage>182</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17699207</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenvinkel</surname><given-names>P</given-names></name></person-group><article-title>Inflammatory and atherosclerosis interactions in the depleted uremic patients</article-title><source>Blood Purif</source><year>2001</year><volume>19</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11114578</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Fang</surname><given-names>CH</given-names></name></person-group><article-title>C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease</article-title><source>Med Hypotheses</source><year>2004</year><volume>62</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">15050096</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenvinkel</surname><given-names>P</given-names></name></person-group><article-title>Inflammation in end-stage renal disease: The hidden enemy</article-title><source>Nephrol</source><year>2006</year><volume>11</volume><fpage>36</fpage><lpage>41</lpage></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>M</given-names></name><name><surname>Moeinzadeh</surname><given-names>F</given-names></name><name><surname>Saadatnia</surname><given-names>M</given-names></name><name><surname>Shahidi</surname><given-names>SH</given-names></name><name><surname>McGee</surname><given-names>JC</given-names></name><name><surname>Minagar</surname><given-names>A</given-names></name></person-group><article-title>Effect of agnesium Supplementation on Carotid Intima-Media Thickness and Flow-Mediated Dilatation among Hemodialysis Patients: A Double-Blind, Randomized, Placebo-Controlled Trial</article-title><source>Eur Neurol</source><year>2013</year><volume>69</volume><fpage>309</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">23548855</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>CL</given-names></name></person-group><article-title>Effects of Zinc Supplementation on Plasma Copper/Zinc Ratios, Oxidative Stress, and Immunological Status in Hemodialysis Patients</article-title><source>Int J Med Sci</source><year>2013</year><volume>10</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">23289009</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahni</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>KL</given-names></name></person-group><article-title>Dietary antioxidants and oxidative stress in predialysis chronic kidney disease patients</article-title><source>J Nephropathology</source><year>2012</year><volume>1</volume><fpage>134</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">24475404</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussein</surname><given-names>N</given-names></name><name><surname>Ah-Sing</surname><given-names>E</given-names></name><name><surname>Wilkinson</surname><given-names>P</given-names></name><name><surname>Leach</surname><given-names>C</given-names></name><name><surname>Griffin</surname><given-names>BA</given-names></name><name><surname>Millward</surname><given-names>DJ</given-names></name></person-group><article-title>Long-chain conversion of [13C] linoleic acid and alpha-linolenic acid in response to marked changes in their dietary intake in men</article-title><source>J Lipid Re</source><year>2005</year><volume>46</volume><fpage>269</fpage><lpage>80</lpage></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Cybulsky</surname><given-names>MI</given-names></name><name><surname>Clinton</surname><given-names>SK</given-names></name><name><surname>Gimbrone</surname><given-names>MA</given-names><suffix>Jr</suffix></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells</article-title><source>Arterioscler Thromb</source><year>1994</year><volume>14</volume><fpage>1829</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">7524649</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>PC</given-names></name></person-group><article-title>Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on &#x02018;Nutrition and autoimmune disease&#x02019; PUFA, inflammatory processes and rheumatoid arthritis</article-title><source>Proceedings of the Nutrition Society</source><year>2008</year><volume>67</volume><fpage>409</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">18847518</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belluzzi</surname><given-names>A</given-names></name><name><surname>Brignola</surname><given-names>C</given-names></name><name><surname>Campieri</surname><given-names>M</given-names></name><name><surname>Pera</surname><given-names>A</given-names></name><name><surname>Boschi</surname><given-names>S</given-names></name><name><surname>Miglioli</surname><given-names>M</given-names></name></person-group><article-title>Effect of an enteric- coated fish oil preparation on relapses in Crohn's disease</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>1557</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8628335</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donadio</surname><given-names>JV</given-names><suffix>Jr</suffix></name><name><surname>Bergstralh</surname><given-names>EJ</given-names></name><name><surname>Offord</surname><given-names>KP</given-names></name><name><surname>Spencer</surname><given-names>DC</given-names></name><name><surname>Holley</surname><given-names>KE</given-names></name></person-group><article-title>A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><fpage>1194</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7935657</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fetterman</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Zdanowicz</surname><given-names>MM</given-names></name></person-group><article-title>Therapeutic potential of n-3 polyunsaturated fatty acids in disease</article-title><source>Am J Health Syst Pharm</source><year>2009</year><volume>66</volume><fpage>1169</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">19535655</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>EB</given-names></name><name><surname>Christensen</surname><given-names>JB</given-names></name></person-group><article-title>The effect of n-3 fatty acids on C- reactive protein levels in patients with chronic renal failure</article-title><source>J Ren Nutr</source><year>2007</year><volume>17</volume><fpage>258</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17586424</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tayyebi-Khosroshahi</surname><given-names>H</given-names></name><name><surname>Houshyar</surname><given-names>J</given-names></name><name><surname>Dehghan-Hesari</surname><given-names>R</given-names></name><name><surname>Alikhah</surname><given-names>H</given-names></name><name><surname>Vatankhah</surname><given-names>A</given-names></name><name><surname>Safaeian</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Effect of treatment with Omega-3 Fatty Acid on C reactive protein and tumor necrosis factor-alfa in hemodialysis patients</article-title><source>Saudi J Kidney Dis Transpl</source><year>2012</year><volume>23</volume><fpage>500</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22569435</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0015e;ahinarslan</surname><given-names>A</given-names></name><name><surname>G&#x000fc;z</surname><given-names>G</given-names></name><name><surname>Mutluay</surname><given-names>R</given-names></name><name><surname>Okyay</surname><given-names>K</given-names></name><name><surname>Demirta&#x0015f;</surname><given-names>C</given-names></name><name><surname>Pa&#x0015f;ao&#x0011f;lu</surname><given-names>H</given-names></name><etal/></person-group><article-title>The impact of dialysis type on biomarkers for cardiovascular diseases</article-title><source>Arch Turk Soc Cardiol</source><year>2011</year><volume>39</volume><fpage>456</fpage><lpage>62</lpage></element-citation></ref></ref-list></back></article>